| Schedule of Significant Expenses of the CODM Function |
The CODM function is regularly provided with the following significant segment expenses: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended
June 30, | | Six Months Ended
June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | | Oncology clinical trial related costs | | $ | 114,339 | | | $ | 67,824 | | | $ | 204,534 | | | $ | 104,187 | | | | | | | | | | | | Compensation related costs, excluding stock-based compensation | | 27,996 | | | 16,800 | | | 54,428 | | | 32,654 | | | Stock-based compensation | | 68,706 | | | 478,784 | | | 141,497 | | | 489,880 | | Other expenses (1) | | 9,455 | | | 5,029 | | | 15,249 | | | 8,567 | | | Total segment expenses | | 220,496 | | | 568,437 | | | 415,708 | | | 635,288 | | | Other income, net | | 4,796 | | | 2,729 | | | 10,584 | | | 6,667 | | | | | | | | | | | | Net loss | | $ | (215,700) | | | $ | (565,708) | | | $ | (405,124) | | | $ | (628,621) | |
(1) Other expenses include general and administrative expenses excluding compensation and stock-based compensation.
|